Symbols / ZVRA $10.49 +0.96% Zevra Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
ZVRA Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 620.11M Enterprise Value 482.21M Income 77.58M Sales 106.47M Book/sh 2.72 Cash/sh 3.25
Dividend Yield — Payout 0.00% Employees 61 IPO — P/E 7.77 Forward P/E 6.90
PEG 10.67 P/S 5.82 P/B 3.86 P/C — EV/EBITDA -2693.90 EV/Sales 4.53
Quick Ratio 5.46 Current Ratio 5.68 Debt/Eq 40.87 LT Debt/Eq — EPS (ttm) 1.35 EPS next Y 1.52
EPS Growth — Revenue Growth 183.40% Earnings 2026-05-06 ROA -1.14% ROE 85.66% ROIC —
Gross Margin 84.52% Oper. Margin 27.30% Profit Margin 78.17% Shs Outstand 59.11M Shs Float 54.43M Short Float 7.60%
Short Ratio 3.03 Short Interest — 52W High 13.16 52W Low 7.01 Beta 0.89 Avg Volume 1.03M
Volume 750.66K Target Price $22.78 Recom None Prev Close $10.39 Price $10.49 Change 0.96%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.78
Mean price target
2. Current target
$10.49
Latest analyst target
3. DCF / Fair value
$-0.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.49
Low
$18.00
High
$26.00
Mean
$22.78

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-16 init BTIG — → Buy $23
2025-11-06 main Canaccord Genuity Buy → Buy $24
2025-11-06 main Cantor Fitzgerald Overweight → Overweight $24
2025-08-13 main JMP Securities Market Outperform → Market Outperform $18
2025-07-10 main Cantor Fitzgerald Overweight → Overweight $29
2025-07-02 init HC Wainwright & Co. — → Buy $26
2025-05-14 reit Cantor Fitzgerald Overweight → Overweight $25
2025-03-13 main Canaccord Genuity Buy → Buy $25
2025-03-13 main Guggenheim Buy → Buy $22
2025-03-13 reit HC Wainwright & Co. Buy → Buy $20
2025-03-12 main Citizens Capital Markets Market Outperform → Market Outperform $18
2025-03-12 reit Cantor Fitzgerald Overweight → Overweight $25
2024-11-20 reit HC Wainwright & Co. Buy → Buy $20
2024-11-14 main Canaccord Genuity Buy → Buy $23
2024-10-11 reit Cantor Fitzgerald — → Overweight —
2024-10-07 init Guggenheim — → Buy $20
2024-10-01 reit Cantor Fitzgerald — → Overweight —
2024-09-30 reit HC Wainwright & Co. Buy → Buy $20
2024-09-24 init JMP Securities — → Market Outperform $17
2024-09-24 main Maxim Group Buy → Buy $25
News
RSS: Latest ZVRA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
106.47
+350.91%
23.61
-14.02%
27.46
+170.26%
10.16
Operating Revenue
106.47
+350.91%
23.61
-14.02%
27.46
+170.26%
10.16
Cost Of Revenue
16.48
+122.22%
7.42
+241.33%
2.17
+878.83%
0.22
Reconciled Cost Of Revenue
16.29
+124.29%
7.26
+274.57%
1.94
+773.42%
0.22
Gross Profit
89.99
+455.65%
16.20
-35.96%
25.29
+154.43%
9.94
Operating Expense
94.22
-8.70%
103.20
+37.80%
74.89
+114.95%
34.84
Research And Development
12.74
-69.73%
42.09
+5.75%
39.81
+101.01%
19.80
Selling General And Administration
77.62
+41.46%
54.87
+59.90%
34.31
+128.18%
15.04
General And Administrative Expense
—
—
—
15.34
Other Gand A
—
—
—
15.34
Total Expenses
110.70
+0.08%
110.61
+43.53%
77.06
+119.79%
35.06
Operating Income
-4.23
+95.13%
-87.00
-75.40%
-49.60
-99.20%
-24.90
Total Operating Income As Reported
-62.94
+27.65%
-87.00
-75.40%
-49.60
-16.54%
-42.56
EBITDA
98.71
+229.20%
-76.40
-75.46%
-43.54
-70.58%
-25.53
Normalized EBITDA
6.77
+108.63%
-78.44
-78.04%
-44.06
-96.29%
-22.45
Reconciled Depreciation
4.05
-36.55%
6.39
+535.09%
1.01
+6.57%
0.94
EBIT
94.66
+214.33%
-82.79
-85.84%
-44.55
-68.30%
-26.47
Total Unusual Items
91.94
+4409.17%
2.04
+295.92%
0.52
+116.72%
-3.08
Total Unusual Items Excluding Goodwill
91.94
+4409.17%
2.04
+295.92%
0.52
+116.72%
-3.08
Special Income Charges
89.61
0.00
0.00
+100.00%
-17.66
Other Special Charges
—
—
—
17.66
Impairment Of Capital Assets
58.71
0.00
—
—
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Pretax Income
86.68
+196.16%
-90.14
-95.75%
-46.05
-71.79%
-26.80
Net Non Operating Interest Income Expense
-1.03
+80.08%
-5.18
-270.26%
3.04
+158.06%
1.18
Interest Expense Non Operating
7.98
+8.52%
7.35
+389.74%
1.50
+348.06%
0.34
Net Interest Income
-1.03
+80.08%
-5.18
-270.26%
3.04
+158.06%
1.18
Interest Expense
7.98
+8.52%
7.35
+389.74%
1.50
+348.06%
0.34
Interest Income Non Operating
6.95
+219.36%
2.17
-52.10%
4.54
+200.13%
1.51
Interest Income
6.95
+219.36%
2.17
-52.10%
4.54
+200.13%
1.51
Other Income Expense
91.94
+4409.17%
2.04
+295.92%
0.52
+116.72%
-3.08
Gain On Sale Of Security
2.33
+14.12%
2.04
+295.92%
0.52
-96.47%
14.58
Tax Provision
3.45
-77.56%
15.37
0.00
+100.00%
-0.03
Tax Rate For Calcs
0.00
-81.05%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
3.66
+754.60%
0.43
0.00
+100.00%
-0.00
Net Income Including Noncontrolling Interests
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Net Income From Continuing Operation Net Minority Interest
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Net Income From Continuing And Discontinued Operation
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Net Income Continuous Operations
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Normalized Income
-5.05
+95.28%
-107.12
-130.05%
-46.56
-96.52%
-23.69
Net Income Common Stockholders
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
1.35
+159.21%
-2.28
-75.38%
-1.30
-8.33%
-1.20
Basic EPS
1.40
+161.40%
-2.28
-75.38%
-1.30
-8.33%
-1.20
Basic Average Shares
55.31
+19.59%
46.25
+30.46%
35.45
+2.79%
34.49
Diluted Average Shares
57.26
+23.81%
46.25
+30.46%
35.45
+2.79%
34.49
Diluted NI Availto Com Stockholders
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Amortization
3.86
-38.06%
6.24
+707.64%
0.77
—
Amortization Of Intangibles Income Statement
3.86
-38.06%
6.24
+707.64%
0.77
—
Depreciation Amortization Depletion Income Statement
3.86
-38.06%
6.24
+707.64%
0.77
—
Depreciation And Amortization In Income Statement
3.86
-38.06%
6.24
+707.64%
0.77
—
Gain On Sale Of PPE
148.32
0.00
—
—
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
284.73
+59.85%
178.13
+3.37%
172.33
+49.41%
115.34
Current Assets
223.01
+159.23%
86.03
-1.05%
86.94
-6.35%
92.83
Cash Cash Equivalents And Short Term Investments
191.01
+174.85%
69.50
+2.60%
67.74
-18.24%
82.85
Cash And Cash Equivalents
62.41
+84.72%
33.78
-21.52%
43.05
-34.24%
65.47
Other Short Term Investments
128.60
+260.13%
35.71
+44.65%
24.69
+42.04%
17.38
Receivables
23.26
+121.32%
10.51
-39.52%
17.38
+109.39%
8.30
Accounts Receivable
9.88
+146.28%
4.01
-75.12%
16.12
+124.34%
7.18
Other Receivables
13.38
+105.91%
6.50
+416.61%
1.26
+12.93%
1.11
Inventory
1.74
-11.68%
1.97
0.00
—
Prepaid Assets
0.95
-8.78%
1.04
-11.52%
1.17
+103.12%
0.58
Restricted Cash
—
—
—
—
Other Current Assets
6.05
+100.73%
3.02
+362.42%
0.65
-41.31%
1.11
Total Non Current Assets
61.72
-32.98%
92.10
+7.86%
85.39
+279.41%
22.51
Net PPE
1.70
+67.92%
1.01
-33.62%
1.53
-14.37%
1.78
Gross PPE
2.02
-26.43%
2.74
-13.32%
3.16
-2.02%
3.23
Accumulated Depreciation
-0.31
+81.81%
-1.73
-5.63%
-1.63
-13.24%
-1.44
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.66
-26.64%
0.90
+12.63%
0.80
+41.34%
0.57
Other Properties
1.22
+7.71%
1.13
-31.64%
1.65
-15.34%
1.95
Leases
0.14
-80.42%
0.71
+0.00%
0.71
+0.00%
0.71
Goodwill And Other Intangible Assets
11.12
-84.91%
73.69
-0.32%
73.93
0.00
Goodwill
4.70
+0.00%
4.70
+0.00%
4.70
0.00
Other Intangible Assets
6.42
-90.69%
68.99
-0.34%
69.23
—
Investments And Advances
47.88
+696.66%
6.01
0.00
-100.00%
20.00
Other Investments
—
—
—
20.00
Other Non Current Assets
1.02
-91.02%
11.38
+14.57%
9.94
+1272.24%
0.72
Total Liabilities Net Minority Interest
130.07
-6.06%
138.46
+25.35%
110.46
+174.65%
40.22
Current Liabilities
39.28
+15.30%
34.06
-53.79%
73.72
+513.16%
12.02
Payables And Accrued Expenses
25.31
-0.58%
25.46
-10.38%
28.40
+360.41%
6.17
Payables
16.19
+23.81%
13.07
-6.52%
13.99
+287.34%
3.61
Accounts Payable
2.48
-81.05%
13.07
-6.52%
13.99
+287.34%
3.61
Current Accrued Expenses
9.12
-26.34%
12.38
-14.12%
14.42
+463.57%
2.56
Total Tax Payable
13.71
0.00
—
—
Income Tax Payable
13.71
0.00
—
—
Current Debt And Capital Lease Obligation
0.42
-0.24%
0.42
-98.90%
38.24
+7867.29%
0.48
Current Debt
—
—
37.70
+709.88%
4.66
Other Current Borrowings
—
—
37.70
+709.88%
4.66
Current Capital Lease Obligation
0.42
-0.24%
0.42
-22.65%
0.54
+13.13%
0.48
Other Current Liabilities
13.55
+65.47%
8.19
+15.76%
7.07
+31.63%
5.37
Total Non Current Liabilities Net Minority Interest
90.80
-13.03%
104.40
+184.12%
36.74
+30.31%
28.20
Long Term Debt And Capital Lease Obligation
62.79
+4.86%
59.88
+984.32%
5.52
-59.53%
13.64
Long Term Debt
61.93
+4.07%
59.50
+1074.58%
5.07
-60.42%
12.80
Long Term Capital Lease Obligation
0.86
+130.91%
0.37
-18.42%
0.46
-45.91%
0.84
Tradeand Other Payables Non Current
7.03
-51.29%
14.43
0.00
—
Other Non Current Liabilities
11.41
-7.16%
12.29
-18.76%
15.12
+247.45%
4.35
Stockholders Equity
154.66
+289.90%
39.67
-35.88%
61.86
-17.65%
75.12
Common Stock Equity
154.66
+289.90%
39.67
-35.88%
61.86
-17.65%
75.12
Capital Stock
0.01
+20.00%
0.01
+25.00%
0.00
+33.33%
0.00
Common Stock
0.01
+20.00%
0.01
+25.00%
0.00
+33.33%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
58.34
+5.60%
55.25
+28.15%
43.11
+21.61%
35.45
Ordinary Shares Number
56.85
+5.93%
53.67
+29.22%
41.53
+20.25%
34.54
Treasury Shares Number
1.48
-5.85%
1.58
+0.00%
1.58
+73.16%
0.91
Additional Paid In Capital
588.46
+5.97%
555.30
+17.48%
472.66
+8.34%
436.27
Retained Earnings
-422.06
+16.47%
-505.29
-26.39%
-399.78
-13.02%
-353.73
Gains Losses Not Affecting Retained Earnings
-0.76
-221.08%
0.63
+1567.44%
-0.04
-138.05%
0.11
Treasury Stock
10.98
+0.00%
10.98
+0.00%
10.98
+45.74%
7.54
Other Equity Adjustments
-0.76
-221.08%
0.63
+1567.44%
-0.04
-138.05%
0.11
Total Equity Gross Minority Interest
154.66
+289.90%
39.67
-35.88%
61.86
-17.65%
75.12
Total Capitalization
216.59
+118.40%
99.17
+48.17%
66.93
-23.87%
87.92
Working Capital
183.73
+253.59%
51.96
+293.12%
13.22
-83.64%
80.81
Invested Capital
216.59
+118.40%
99.17
-5.22%
104.63
+19.01%
87.92
Total Debt
63.21
+4.83%
60.30
+37.77%
43.77
+209.88%
14.12
Net Debt
—
25.72
—
—
Capital Lease Obligations
1.28
+61.36%
0.79
-20.72%
1.00
-24.49%
1.32
Net Tangible Assets
143.53
+521.81%
-34.03
-182.06%
-12.06
-116.06%
75.12
Tangible Book Value
143.53
+521.81%
-34.03
-182.06%
-12.06
-116.06%
75.12
Available For Sale Securities
47.88
+696.66%
6.01
—
—
Derivative Product Liabilities
9.57
-46.22%
17.80
+10.58%
16.10
+57.81%
10.20
Interest Payable
—
—
—
—
Investmentin Financial Assets
47.88
+696.66%
6.01
0.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-1.60
+97.71%
-69.67
-107.74%
-33.53
-79.17%
-18.72
Cash Flow From Continuing Operating Activities
-1.60
+97.71%
-69.67
-107.74%
-33.53
-79.17%
-18.72
Net Income From Continuing Operations
83.23
+178.88%
-105.51
-129.13%
-46.05
-72.00%
-26.77
Depreciation Amortization Depletion
4.05
-36.55%
6.39
+535.09%
1.01
+6.57%
0.94
Depreciation And Amortization
4.05
-36.55%
6.39
+535.09%
1.01
+6.57%
0.94
Other Non Cash Items
3.33
+6.77%
3.12
+1272.25%
0.23
-98.73%
17.89
Stock Based Compensation
12.63
-15.24%
14.91
+150.35%
5.95
+38.66%
4.29
Provisionand Write Offof Assets
11.68
+103.29%
5.75
0.00
—
Asset Impairment Charge
58.71
0.00
—
—
Deferred Tax
3.45
-77.57%
15.37
0.00
—
Deferred Income Tax
3.45
-77.57%
15.37
0.00
—
Operating Gains Losses
-148.89
-9090.86%
-1.62
-2942.11%
0.06
+100.37%
-15.24
Gain Loss On Investment Securities
-2.18
-5.88%
-2.06
-2198.98%
0.10
+100.65%
-15.16
Unrealized Gain Loss On Investment Securities
-0.15
-927.78%
0.02
+102.94%
-0.61
-206.24%
0.58
Net Foreign Currency Exchange Gain Loss
1.55
+606.85%
0.22
+210.61%
-0.20
-117.58%
-0.09
Gain Loss On Sale Of PPE
0.06
-71.10%
0.22
+38.85%
0.16
+1644.44%
0.01
Change In Working Capital
-26.51
-268.63%
-7.19
-222.25%
5.88
+1549.01%
-0.41
Change In Receivables
-11.98
-274.39%
6.87
+175.66%
-9.08
-34.05%
-6.77
Change In Inventory
-1.30
+85.29%
-8.87
-4407.77%
0.21
+40.14%
0.15
Change In Prepaid Assets
-2.94
-32.09%
-2.23
-1565.79%
0.15
+117.00%
-0.89
Change In Payables And Accrued Expense
-15.59
-333.21%
-3.60
-132.33%
11.13
+255.48%
3.13
Change In Other Working Capital
6.68
+1450.58%
0.43
-86.66%
3.23
-14.57%
3.78
Change In Other Current Assets
0.45
0.00
-100.00%
0.32
-51.58%
0.66
Change In Other Current Liabilities
-1.83
-977.51%
0.21
+364.56%
-0.08
+82.94%
-0.46
Investing Cash Flow
18.13
+181.80%
-22.16
-27.44%
-17.39
+52.64%
-36.72
Cash Flow From Continuing Investing Activities
18.13
+181.80%
-22.16
-27.44%
-17.39
+52.64%
-36.72
Net PPE Purchase And Sale
-0.39
0.00
+100.00%
-0.30
-218.28%
-0.09
Purchase Of PPE
-0.83
0.00
+100.00%
-0.30
-218.28%
-0.09
Sale Of PPE
0.45
0.00
—
—
Capital Expenditure
-0.83
—
-0.30
-218.28%
-0.09
Net Investment Purchase And Sale
18.51
+214.56%
-16.16
-221.45%
13.31
+159.05%
-22.54
Purchase Of Investment
-309.99
-653.11%
-41.16
+10.16%
-45.81
-92.00%
-23.86
Sale Of Investment
328.50
+1214.00%
25.00
-57.71%
59.12
+4361.96%
1.32
Net Business Purchase And Sale
—
0.00
+100.00%
-30.40
-115.76%
-14.09
Purchase Of Business
—
0.00
+100.00%
-30.40
-115.76%
-14.09
Net Other Investing Changes
—
-6.00
—
—
Financing Cash Flow
12.06
-85.31%
82.11
+188.46%
28.46
+240.80%
8.35
Cash Flow From Continuing Financing Activities
12.06
-85.31%
82.11
+188.46%
28.46
+240.80%
8.35
Net Issuance Payments Of Debt
0.00
-100.00%
16.29
-34.57%
24.89
+94.74%
12.78
Issuance Of Debt
0.00
-100.00%
58.99
+39.03%
42.43
+231.49%
12.80
Repayment Of Debt
0.00
+100.00%
-42.70
-143.50%
-17.54
-109500.00%
-0.02
Long Term Debt Issuance
0.00
-100.00%
58.99
+39.03%
42.43
+231.49%
12.80
Long Term Debt Payments
0.00
+100.00%
-42.70
-143.50%
-17.54
-109500.00%
-0.02
Net Long Term Debt Issuance
0.00
-100.00%
16.29
-34.57%
24.89
+94.74%
12.78
Short Term Debt Issuance
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
8.64
-86.61%
64.52
+2326.33%
2.66
+156.30%
-4.72
Common Stock Payments
—
0.00
+100.00%
-3.45
+27.02%
-4.72
Repurchase Of Capital Stock
—
0.00
+100.00%
-3.45
+27.02%
-4.72
Proceeds From Stock Option Exercised
3.80
+38.48%
2.74
+1157.80%
0.22
-32.72%
0.32
Net Other Financing Charges
-0.37
+74.17%
-1.44
-308.09%
0.69
+2196.97%
-0.03
Changes In Cash
28.59
+394.23%
-9.72
+56.73%
-22.46
+52.30%
-47.08
Effect Of Exchange Rate Changes
0.03
-93.83%
0.45
+931.82%
0.04
-78.43%
0.20
Beginning Cash Position
33.78
-21.52%
43.05
-34.24%
65.47
-41.73%
112.35
End Cash Position
62.41
+84.72%
33.78
-21.52%
43.05
-34.24%
65.47
Free Cash Flow
-2.43
+96.51%
-69.67
-105.92%
-33.83
-79.86%
-18.81
Interest Paid Supplemental Data
5.33
+1.27%
5.26
+1053.95%
0.46
+42.06%
0.32
Amortization Of Securities
-3.13
-251.46%
-0.89
0.00
—
Common Stock Issuance
8.64
-86.61%
64.52
+956.60%
6.11
0.00
Issuance Of Capital Stock
8.64
-86.61%
64.52
+956.60%
6.11
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category